Safety of Hepatitis Vaccine | Hepatitis Central

Safety and Immunogenicity of
Hepatitis A Vaccine in Patients With Chronic Liver Disease

table 1. Subject Characteristics at Enrollment

	Healthy (n = 188)	Chronic Hepatitis C Vaccinated With Hepatitis A Vaccine (n = 104)	Chronic Hepatitis C Vaccinated With Hepatitis B Vaccine (n = 67)	Chronic Hepatitis B (n = 46)	Other CLD (n = 70)

Mean age (range) (yr)	39.8 (19-73)	40.9 (23-69)	45.0 (25-67)	38.3 (18-67)	43.1 (20-70)
Gender ratio (M/F)^*	47.8/52.2	63.8/35.2	68.7/31.3	71.7/28.3	53.6/46.4
Serological status	seronegative for markers for hepatitis A, B and C	anti-HCV positive	anti-HCV positive	HBsAg positive in two blood samples 6 months apart	seronegative for markers for hepatitis A, B and C
		seronegative for markers for hepatitis A	seronegative for markers for hepatitis B	seronegative for markers for hepatitis A

NOTE. ANOVA of mean ages was not significant for sex (P = .91) and interaction sex-group (P = .67), but was significant for group (P = .0015). Ratio of males to females was significantly different (Fisher’s Exact test, P = .002). Abbreviations: hepatitis A viral marker, anti-HAV; hepatitis C viral marker, anti-HCV; hepatitis B viral marker, HBsAg, anti-HBs, anti-HBc, anti-HDV, anti-HBe. ^* Gender ratio expressed in percentage (%). Age and sex not recorded for one subject.